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Barbara Piras1 and Marc Miravitlles2*The definition of chronic obstructive pulmonary dis-
ease (COPD) as a preventable and treatable condition
characterized by a not completely reversible chronic
airflow obstruction [1] is so broad and imprecise that
many different types of patients with distinct clinical
characteristics, prognosis and response to treatments
may fit in. These different types are now described as
“clinical phenotypes” and the interest in their defin-
ition and characterisation is growing [2]. Among these
phenotypes, the so-called overlap of syndromes with
airflow obstruction is usually poorly considered [3].
In a first step of phenotyping, a COPD patient can
potentially be classified as a predominant parenchymal
destructive or predominant airflow limitation phenotype
by using a few clinical, radiological and functional findings
[4]. However, when a patient presents characteristics and
symptoms of two or more respiratory diseases at the same
time, this is described as an overlap syndrome. In particu-
lar, the asthma-COPD overlap phenotype has been
described as symptoms of increased variability of airflow
in association with an incompletely reversible airflow
obstruction [5]. From a clinical point of view it usually
corresponds to individuals diagnosed with asthma before
the age of 40 who, at an older age, fulfil the criteria for
COPD [6]. Recent estimations of its prevalence report that
about 13-20% of subjects with COPD have the overlap
phenotype [6,7], with an increasing trend in the elderly
population (up to 50% in those aged over 70 years) [7].
Since they have been systematically excluded from both
COPD and asthma pharmacological clinical trials as not
being “pure” subjects, it is clear that we cannot really know
the response to pharmacological treatment of a significant
number of patients with COPD.
Increased reversibility is one of the key differential
aspects of individuals with the overlap asthma-COPD
phenotype. Reversibility in COPD is not only possible* Correspondence: marcm@separ.es
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distribution, and reproduction in any mediumbut it is also not so infrequent: indeed, significant re-
versibility in COPD is observed frequently in everyday
clinical practice and in a series of patients included in the
newly designed clinical trials [8]. Over one half to almost
two-thirds of the patients with moderate-to-very-severe
COPD participating in the large clinical trial UPLIFT met
the most commonly used criteria for acute bronchodilator
responsiveness [9]. In a recent study of COPD patients
without a prior history of asthma, 44% of the subjects
showed a positive bronchodilator test with an inverse cor-
relation between bronchodilator reversibility and the
GOLD severity stages [10].
Reversibility, however, has not been considered to be a
reliable parameter to diagnose or classify patients; the
reason being that a patient may be reversible or irrevers-
ible in different determinations at different time points
[11]. This is a consequence of dichotomising a continu-
ous variable as positive or negative. In fact, this approach
could be valid for epidemiologic studies but should never
be used to guide clinical decisions in an individual
patient. Reversibility in clinical practice must be consid-
ered as a continuous variable, and therapeutic decisions
should be made according to the magnitude of the
change. One example will help to explain this concept: a
patient with a reversibility of 11.8% in forced expiratory
volume in the 1st second (FEV1) has the same kind of re-
versibility as a patient with an increase of 12.2%, despite
the first being negative and the latter positive. In con-
trast, the latter patient (the one with an increase in FEV1
of 12.2%) may have a different response to treatment
compared to a patient with a reversibility of 45%, despite
the fact of both being positive.
Why is it so important to identify the overlap phenotype?
From a clinical point of view, it is composed of COPD
patients with increased reversibility and/or of smoker asth-
matics with fixed airflow obstruction. Are they just the
same patients with different names? Probably yes. In COPD,
the positive bronchodilator response is associated with an
enhanced eosinophilic inflammation in the airways in con-
trast to the predominance of neutrophils in irreversibleCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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ciated with CD4+ T lymphocytes and eosinophils, and it is
very responsive to corticosteroids. Conversely, neutrophilic
inflammation has been linked to airflow obstruction severity
both in asthma and COPD. Severe asthmatics, those with
fixed airflow obstruction or those with a history of smoking,
exhibit higher numbers of neutrophils in bronchoalveolar
lavage fluid and biopsies [13-15]. Sputum neutrophils in
stable COPD are negatively correlated with the FEV1 per-
cent predicted and accelerated FEV1 decline, especially in
patients without bronchodilator reversibility [15,16]. Neu-
trophilic and eosinophilic inflammations demonstrate
different responses to corticosteroid treatment. These
observations suggest that patients with COPD and the
overlap phenotype may have some degree of eosinophilic
inflammation which is more responsive to corticosteroids
and has a somewhat better prognosis than patients with
irreversible airway obstruction. In addition, reversible
patients with COPD also present more eosinophils in spu-
tum and higher concentrations of exhaled nitric oxide
(NO) [11,15,17,18].
During exacerbations the airway inflammation becomes
even more intense, with recruitment of neutrophils and
eosinophils and increased CD4+ lymphocytes in the
bronchial mucosa [19,20]. Studies in bronchial biopsies of
exacerbated patients with mild to moderate COPD have
shown a 30-fold increase in the total number of eosinophils
and a 3-fold increase of neutrophils in their bronchial mu-
cosa [21]. This increase in eosinophils during exacerbations
may explain, at least in part, the clinical improvement asso-
ciated with the use of corticosteroids in exacerbations of
COPD [22]. Interestingly, patients with the overlap pheno-
type are also more likely to be frequent exacerbators
(defined as the presence of two or more exacerbations per
year), to have a worse quality of life, more respiratory symp-
toms [6,15] and to consume from 2 to 6-fold the resources
used by asthma or COPD patients [23]. In addition, an
increased mortality has been observed in COPD patients
with peripheral eosinophilia [24].
How may all these findings affect the management
of our patients? It is clear that not all COPD patients
have the same clinical and inflammatory characteristics
and not all types of patients are represented in clinical
trials. The GOLD guidelines suggest adding inhaled
corticosteroids (ICs) to the treatment of patients with
severe or exacerbated COPD [1]. This recommendation
does not take into account the possible responsiveness
to ICs. Neutrophilic inflammation present in most
patients with COPD, irrespective of the number of
exacerbations, does not respond to ICs [25]. On the
contrary, patients with a component of eosinophilic in-
flammation show a significant improvement in bron-
chial inflammation and, more interestingly, a clinical
improvement, even in mild to moderate stages of COPD[9,26,27]. In particular, one randomised trial demonstrated
that prescribing ICs according to the intensity of eosino-
philic inflammation in sputum was significantly superior
in preventing exacerbations compared to the prescription
of ICs according to guidelines [28]. This demonstrates that
guidelines must be improved with recognition of persona-
lised treatment and patterns of therapy guided by pheno-
types instead of severity of airflow obstruction [29,30].
Nowadays, only the Canadian and the Japanese guidelines
consider these particular characteristics of patients with
COPD. The Canadian guidelines specify that: “if the
asthma component (in COPD) is prominent, earlier intro-
duction of ICs may be justified” [31]; the Japanese guide-
line dedicates a chapter to “Treatment of COPD
complicated by asthma” [32]. The future Spanish guide-
lines of COPD will direct treatment according to pheno-
types, and the overlap phenotype will be one of them [33].
We should not forget that COPD patients are
mostly elderly, with comorbidities that require numer-
ous drugs; therefore, avoiding the use of unnecessary
medications, which may be associated with frequent
and serious side effects and increased costs, must be
mandatory.
Obviously, the characterization of phenotypes will re-
quire more time to be spent for the clinical evaluation of
patients, but with simple investigations we should be
able to diagnose the overlap phenotype in COPD [34].
Recently, by consensus a group of experts established
the diagnostic criteria for the overlap phenotype. To be
diagnosed with an overlap phenotype, a patient must ful-
fill 2 major criteria or one major and two minor among
the following: A) Major criteria: very positive broncho-
dilator response (> 400 ml and> 15% in FEV1), sputum
eosinophilia or previous diagnosis of asthma. B) Minor
criteria: increased total serum IgE, previous history of
atopy or positive bronchodilator test (> 200 mL and
> 12% in FEV1) on at least two occasions [35]. These are
quite restrictive criteria and a very conservative ap-
proach until we have more evidence from large clinical
trials about characterization and differential response of
the overlap phenotype. Whether you believe in the hy-
pothesis of asthma and COPD as two expressions of the
same disease (the Dutch hypothesis) or not, patients
with overlap syndrome are surely different from both
those with COPD and those with asthma. In many
aspects they share characteristics of the two diseases,
but with significant differences in clinical features such
as age, lung function and cardiovascular comorbidity
[36] and, even more importantly, they respond differ-
ently to existing anti-inflammatory therapies.
It is time to recognize that COPD is not a single easily
treatable disease, but that it has truly different clinical,
radiological and functional aspects that can mix together in
distinct phenotypes, and treatment has to be tailored to the
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obstruction [37].
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